Dr.Martinez said:

Another six months, another 7kg, no new side effects, and my reading of the dose-response says the last two steps were never going to be worth what…

Second this. Nothing to add that would improve it.

Dr.Martinez said:

Another six months, another 7kg, no new side effects, and my reading of the dose-response says the last two steps were never going to be worth what…

Coming at Dr.Martinez’s question from a different direction. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.

Ask again with the specifics and you will get a better answer than this one.

Adding the numbers, since they settle part of this. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

I would rather be corrected than agreed with, if it comes to it.

One thing that is still open after Dr.Martinez’s answer:

How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?

PeptideSynthNJ said:

Practical: whatever you change, write down the date and the reason.

Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.